Navigation Links
Increasing Use of Allergan's Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
Date:12/3/2013

BURLINGTON, Mass., Dec. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the use of Allergan's Botox for the prophylactic treatment of chronic migraine will increase modestly in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan) through 2022, despite lingering clinical and market access hurdles. The drug's expanding role, especially in the United States, coupled with its premium price, will propel its major-market sales for migraine to nearly $850 million in 2022. Greater use of Botox will help drive 4 percent annual growth of the total migraine market—which includes both episodic and chronic migraine—which Decision Resources forecasts will expand from nearly $3.6 billion in 2012 to $5.4 billion in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Migraine finds that the expected launch of two premium-priced nontriptan therapies for the acute treatment of migraine, Allergan's Levadex and CoLucid Pharmaceuticals' 5-HT1F receptor agonist lasmiditan, will also fuel the migraine market growth through 2022. As therapeutic alternatives for triptan nonresponders, patients unable to tolerate triptans, or, in the case of lasmiditan, patients in whom triptans are contraindicated, these agents are expected to earn combined sales accounting for 25 percent of the total migraine market in 2022.

The findings also reveal that the projected launch of APR Applied Pharma Research/tesa Labtec's Zolmitriptan RapidFilm (zolmitriptan oral dispersible film) in additional markets and the launch of four novel triptan reformulations in the United States through 2017 will partially offset generic erosion of this drug class. Emerging reformulations include NuPathe's sumatriptan transdermal patch Zecuity, IntelGenx/RedHill Biopharma's rizatriptan oral film (INT-0008), Avanir Pharmaceuticals/OptiNose's sumatriptan intranasal powder (AVP-825) and Suda's sumatriptan oral spray (SUD-001). Although these niche products are forecast to garner modest patient shares, their combined sales will contribute nearly 15 percent market share at end of our forecast period.

"Although the triptan drug class is crowded and increasingly generic, opportunity exists for alternative acute antimigraine therapies that offer unique mechanisms of action or improved efficacy and/or safety profiles," said Decision Resources Senior Director Bethany A. Kiernan, Ph.D. "At the same time, in the forecasted absence of any new prophylactic therapies, owing in large part to a small development pipeline, improved prophylactic therapies remain one of the greatest unmet needs in migraine treatment."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Increasing Incidence of Cardiovascular Diseases to Drive The Cardiovascular Devices Market in Emerging Countries
2. Pharma Execs Continue Looking For Growth Opportunities In Spite Of Increasing Regulatory Challenges: KPMG Survey
3. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
4. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
5. Patient Monitoring Devices Market to 2017 - Increasing Use of Wireless Remote Patient Monitoring to be the Key Technology Trend
6. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
7. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
8. Patient Monitoring Devices Market in Emerging Countries (China, India, Brazil) to 2017 - Increasing Government Spending and Foreign Direct Investment (FDI) to Drive Future Growth
9. RMANJ Research Demonstrates That Egg Freezing Prior To IVF Yields Positive Outcomes Without Increasing Risk Of Aneuploidy
10. Global Hospital Supplies Market to 2018 - Increasing Preference for Electro-mechanical Tables over Conventional Hydraulic Models to Drive Market Growth: MarketResearchReports.Biz
11. AssureRx Health Expands Management Team to Support Increasing Business Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):